Pilot Study of Intratumoral Immunotherapy with Cowpea Mosaic Virus Nanoparticles: Safety in Refractory Canine Oral Tumors
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c00100 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Pablo Delgado-Bonet und 10 weiteren Autor:innen. Beteiligte Einrichtung: Unidad de Investigación Biomédica (UIB-UAX), Universidad Alfonso X el Sabio, Madrid 28691, Spain. Hauptthemen laut MEDLINE: Mouth Neoplasms, Immunotherapy, Nanoparticles, Comovirus. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Oral tumors (squamous cell carcinoma, malignant melanoma, and fibrosarcoma) represent 6-7% of all canine cancers. Given that these tumors have a high local recurrence rate and metastatic potential, conventional therapies have suboptimal response rates, leading to poor patient outcomes. Here, we report the use of intratumoral virus-like particles from cowpea mosaic virus (CPMV) in four canine patients with recurrent oral malignant tumors and lymph node metastasis. All tumors were nonresponders to chemotherapy and had a mild initial response to CPMV intratumoral immunotherapy without any serious immune-related adverse effects. None of the patients developed pulmonary metastasis during follow-up, although local progression was seen in all the patients. Furthermore, tumor-infiltrated immune T cells increased in number after the intratumoral immunotherapy with CPMV, suggesting activation of the tumor microenvironment. All the patients had a rapid decrease in the tumor-promoting chemokines IL-8 and CXCL1, which could indicate that a decrease in metastatic potential could have been generated by the CPMV immunotherapy. The increased number of infiltrated immune cells, the decrease in some pro-tumoral chemokines, and the absence of adverse effects suggest that CPMV could be a safe treatment and should be further explored as a novel therapy for canine oral tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unidad de Investigación Biomédica (UIB-UAX), Universidad Alfonso X el Sabio, Madrid 28691, Spain.
- Small Animal Hospital, University of Glasgow, Glasgow G61 1QH, Scotland, U.K.
- Department of Microbiology and Immunology and Dartmouth Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire 03756, United States.
- Hospital Clínico Veterinario, Universidad Alfonso X el Sabio, Madrid 28691, Spain.
- Institute of Laboratory Animal Science, University of Zurich, Schlieren 8952, Switzerland.
- Aquila Data Analytics, LLC., Concord, New Hampshire 03766, United States.
ORCID-Profile: Pablo Delgado-Bonet, Nicole F Steinmetz, Ana Judith Perisé-Barrios
Förderung
- NCI NIH HHS
- NIH HHS
- NIGMS NIH HHS
- National Cancer Institute
- National Institute of General Medical Sciences
- Swiss Cancer Research
- Santander Universidades-Fundaci?n Universidad Alfonso X el Sabio
Zitieren
APA
Delgado-Bonet, P., Arias-Pulido, H., Del Castillo Magan, N., Emilia Zimmermann, A. B., Schaafsma, E., Vom Berg, J., Vázquez, F., Beiss, V., Steinmetz, N. F., Fiering, S., & Perisé-Barrios, A. J. (2025). Pilot Study of Intratumoral Immunotherapy with Cowpea Mosaic Virus Nanoparticles: Safety in Refractory Canine Oral Tumors. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00100
Vancouver
Delgado-Bonet P, Arias-Pulido H, Del Castillo Magan N, Emilia Zimmermann AB, Schaafsma E, Vom Berg J, et al. Pilot Study of Intratumoral Immunotherapy with Cowpea Mosaic Virus Nanoparticles: Safety in Refractory Canine Oral Tumors. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00100
BibTeX
@article{DelgadoBonet2025,
author = {Delgado-Bonet, Pablo and Arias-Pulido, Hugo and Del Castillo Magan, Noemí and Emilia Zimmermann, Anna Barbara and Schaafsma, Evelien and Vom Berg, Johannes and Vázquez, Fernando and Beiss, Veronique and Steinmetz, Nicole F and Fiering, Steven and Perisé-Barrios, Ana Judith},
title = {Pilot Study of Intratumoral Immunotherapy with Cowpea Mosaic Virus Nanoparticles: Safety in Refractory Canine Oral Tumors},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c00100}
}
EUVIMED